U.S. Markets open in 9 hrs 20 mins

Blog Exposure - ZIOPHARM Updated on Key Clinical Programs and Corporate Development Activities

LONDON, UK / ACCESSWIRE / January 11, 2018 / Active-Investors.com has just released a free research report on ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZIOP as the Company's latest news hit the wire. On January 09, 2018, the Company announced that it provided an update on its important clinical programs and corporate development activities during the 36th Annual J.P. Morgan Healthcare Conference. Register today and get access to over 1000 Free Research Reports by joining our site below:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ZIOPHARM Oncology most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Ziopharm Implementing New Paradigm for Production of TCR with Sleeping Beauty Non-Viral Platform

Ziopharm's immunotherapies in clinical trials are based on two powerful platforms. The Company has shown that it can super-charge a patient's own immune system with controlled, local production of IL-12. It can also provide a new immune response infusing genetically modified T cells with a unique and advantageous manufacturing process. Ziopharm is implementing a new paradigm for production of genetically modified T cells with our Sleeping Beauty (SB) non-viral platform and proprietary membrane bound IL-15 which enables very rapid manufacture of CAR- and TCR-modified cells at low cost and scale.

Updates on Clinical Programs and Cell Therapies

  • Ziopharm, in partnership with Intrexon Corp., is advancing Ad-RTS-hIL-12 + veledimex, or controlled interleukin-12 (IL-12), as a gene therapy for recurrent glioblastoma (rGBM). A Phase-1 trial demonstrated the safety of controlled local expression of IL-12, which can turn cold tumors hot, which could have a profound impact for oncology.
  • The Company announced the initiation of a Phase-I clinical trial to evaluate Ad-RTS-hIL-12 + veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with rGBM. Ziopharm updated guidance on its planned pivotal trial and will initiate in the second half of 2018.
  • Ziopharm has designed the randomized control trial to evaluate controlled IL-12 for the treatment of patients with rGBM and following meetings with US and European regulators is completing Chemistry Manufacturing and Control technical requirements. The Company is simultaneously working on accumulating additional clinical data from the open Phase-1 trials, including the combination trial.
  • The Company, in collaboration with Intrexon and with MD Anderson Cancer Center, the National Cancer Institute (NCI) and Merck KGaA, Darmstadt, Germany, is developing chimeric antigen receptor (CAR) T cell (CAR+ T) and T-cell receptor (TCR) T cell (TCR+ T) therapies.

First Point-of-Care Clinical Trial Expected in 2018

Ziopharm is advancing its non-viral Sleeping Beauty (SB) platform towards P-O-C for the very rapid manufacturing of genetically modified CAR+ T cells, with the first clinical trial utilizing this approach. The trial is likely to begin this year. Data supporting P-O-C were presented at the 59th American Society of Hematology Annual Meeting in December 2017. The Company expects to initiate the third-generation P-O-C study, which leverages SB to manufacture CAR+ T cells co-expressing a membrane-bound interleukin-15, or mbIL15, in less than two days.

Phase-1 Study of SB-Modified TCRs to Begin in Second Half of 2018

The Company updated guidance on the anticipated start of the National Cancer Institute (NCI)-led Phase-1 trial to evaluate adoptive cell transfer (ACT)-based immunotherapies genetically modified using the SB transposon/transposase system to express TCRs for the treatment of solid tumors. In January 2017, Ziopharm, Intrexon, and the NCI signed Cooperative Research and Development Agreement for the development of ACT based immunotherapies genetically modified using the SB transposon/transposase system to express TCRs to treat patients with advanced cancers.

Phase-1 Study of CD33-Specific CAR+T therapy in AML Underway

The Company is enrolling in the Phase-1 adoptive cellular therapy clinical trial of CD33-specific CAR+ T cell therapy in patients with refractory/recurrent Acute Myeloid Leukemia (AML). The trial is enrolling at The University of Texas MD Anderson Cancer Center. The data are expected to serve as the basis for evaluating CD33 as a potential target for further development using very rapid non-viral manufacturing of T cells under P-O-C.

About ZIOPHARM Oncology, Inc.

Founded in 1998, Ziopharm Oncology, Inc. is a biopharmaceutical company focused on the discovery and development of new cancer therapies. The Company employs novel gene expression, control and cell technologies to deliver safe, effective and scalable cell-based therapies for the treatment of cancer and graft-versus-host-disease (GvHD), a type of auto-immune disease. ZIOPHARM is headquartered in Boston, Massachusetts.

Stock Performance Snapshot

January 10, 2018 - At Wednesday's closing bell, ZIOPHARM Oncology's stock marginally rose 0.61%, ending the trading session at $4.13.

Volume traded for the day: 1.11 million shares.

After yesterday's close, ZIOPHARM Oncology's market cap was at $586.29 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors